|
US2811483A
(en)
*
|
1954-12-09 |
1957-10-29 |
Pfizer & Co C |
Pharmaceutical composition and process for preparing the same
|
|
FR1172087A
(fr)
*
|
1956-01-25 |
1959-02-05 |
Bellon Labor Sa Roger |
Perfectionnements concernant l'enrobage de préparations à effet retardé et à effet soutenu
|
|
US2921001A
(en)
*
|
1957-04-16 |
1960-01-12 |
Sterling Drug Inc |
Multi-layered pill or tablet with indicating lamination
|
|
NL109170C
(pt)
*
|
1958-02-03 |
|
|
|
|
GB906422A
(en)
*
|
1958-05-02 |
1962-09-19 |
Wellcome Found |
Improvements in and relating to prolonged acting pharmaceutical preparations
|
|
US3131123A
(en)
*
|
1959-03-13 |
1964-04-28 |
Lab Francais De Therapeutique |
Enteric tablets and manufacture thereof
|
|
US3181998A
(en)
*
|
1960-08-12 |
1965-05-04 |
Joseph L Kanig |
Tablet disintegration
|
|
US3147187A
(en)
*
|
1962-09-10 |
1964-09-01 |
Don Hall Lab |
Sustained release pharmaceutical
|
|
US5019302A
(en)
*
|
1986-03-12 |
1991-05-28 |
Washington University Technology Associates, Inc. |
Method for granulation
|
|
US6632429B1
(en)
|
1999-12-17 |
2003-10-14 |
Joan M. Fallon |
Methods for treating pervasive development disorders
|
|
US20070053895A1
(en)
|
2000-08-14 |
2007-03-08 |
Fallon Joan M |
Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
|
|
US8030002B2
(en)
|
2000-11-16 |
2011-10-04 |
Curemark Llc |
Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
US9320780B2
(en)
|
2008-06-26 |
2016-04-26 |
Curemark Llc |
Methods and compositions for the treatment of symptoms of Williams Syndrome
|
|
WO2010002972A1
(en)
|
2008-07-01 |
2010-01-07 |
Curemark, Llc |
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
|
|
US10776453B2
(en)
|
2008-08-04 |
2020-09-15 |
Galenagen, Llc |
Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
|
|
US20100092447A1
(en)
|
2008-10-03 |
2010-04-15 |
Fallon Joan M |
Methods and compositions for the treatment of symptoms of prion diseases
|
|
WO2010080835A1
(en)
|
2009-01-06 |
2010-07-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention oral infections by e. coli
|
|
CN102300989B
(zh)
|
2009-01-06 |
2015-12-09 |
柯尔朗恩有限责任公司 |
用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
WO2011050135A1
(en)
|
2009-10-21 |
2011-04-28 |
Curemark Llc |
Methods and compositions for the prevention and treatment of influenza
|
|
EP3736315A1
(en)
*
|
2010-06-15 |
2020-11-11 |
University Of South Florida |
Exothermic reaction compositions
|
|
GB2497715A
(en)
*
|
2010-11-19 |
2013-06-19 |
Curemark Llc |
Preparation and use of combination enzyme and gastriontestinal modulator delivery systems
|
|
AU2012245287B2
(en)
|
2011-04-21 |
2017-04-13 |
Curemark, Llc |
Compounds for the treatment of neuropsychiatric disorders
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|